Reduction of Psoriasis Following Liraglutide Therapy in Terms of PASI and DLQI
Conditions
Brief summary
To examine GLP-1 receptors in skin of psoriasis patients compared with the skin of humans with no skin disease
Interventions
DRUGLiraglutide
Victoza® is supplied in pens for injection containing 18 mg of the GLP-1 agonist liraglutide in 3 mL sterile water with disodiumphosphate and propylene glycol, and phenol for conservation (pH 8.15). Commercial pens will be used and the information given in the packaging will be applicable. The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. The injection is administered once daily in the morning. The maximal plasma concentration is reached 8-12 hours after subcutaneous injection. The half-life in plasma is approximately 13 hours. The duration of effect is 24 hours.
DRUGPlacebo
The placebo pens contain saline and are administered in the same way and volume as Victoza. The placebo pens are specially prepared for this study and will be used in the study only
Sponsors
University Hospital, Gentofte, Copenhagen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
4.3 Inclusion Criteria * Caucasians above 18 years of age * Plaque psoriasis * PASI score \>10 * No treatment or stable treatment of psoriasis during at least 3 months before inclusion * Steady weight through 3 months with a body mass index (BMI) above 27 kg/m2 * Normal blood pressure * Spiral or hormonal birth control for fertile women during the entire treatment period and at least 3 days after the end of the treatment period (\ 5 times the plasma half-life) 4.4
Exclusion criteria
* Psoriasis arthritis * Fasting plasma glucose \> 7.5 mmol/L or HbA1c \> 7.5% * Type 1 diabetes * Treatment for type 2 diabetes with GLP-1-based medicine (DDP-4-inhibitors or GLP-1-receptor-agonists) * Heart failure, NYHA class III-IV * Uraemia, end-stage renal disease, or any other cause of impaired renal function with s-creatinine \>150 µM and/or albuminuria * Liver disease (alanine amino transferase (ALAT) and/or aspartate amino transferase (ASAT) \>2 x upper normal serum levels) * Anaemia * Acute or chronic pancreatitis * Struma or thyroid cancer * Pregnancy or breast feeding * Inability to complete the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in PASI and DLQI | 2 months |
Countries
Denmark
Contacts
Primary ContactAnnesofie Faurschou, MD PhD
Outcome results
None listed